Press Room

UK News

12 December 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer

2 October 2019
New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment

21 June 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test

4 June 2019
Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

25 March 2019
Evidence from UK hospitals supports the value of the Oncotype DX test in avoiding unnecessary chemotherapy for patients with node-positive breast cancer

19 December 2018
NICE expands recommendation for the Oncotype DX test to more patients with early-stage breast cancer

11 December, 2018
New long-term evidence from large study reinforces value of the Oncotype DX Breast Recurrence Score test to guide adjuvant chemotherapy treatment, confirming TAILORx conclusions

22 October, 2018
New real-world evidence confirms value of the Oncotype DX test in clinical practice for patients with early-stage breast cancer

3 June, 2018
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving

11 December, 2017
New results from large registry with 10-year follow up show excellent outcomes for patients with low Oncotype DX Breast Recurrence Score® results treated with hormonal therapy alone

11 September 2017
Genomic test shows that half of under-40s with early breast cancer have excellent prognosis despite not having chemotherapy treatment

12 July 2017
Updated St. Gallen International Breast Cancer Guidelines reinforce important role of genomic testing in treatment of early breast cancer

13 June 2017
New data show important role of genomic testing in treatment of older breast cancer patients

20 March 2017
Genomic Health’s Oncotype DX breast cancer test can significantly improve patient outcomes for node-positive patients, international studies reveal

6 February 2017
NHS adoption of Oncotype DX test leads to substantial reduction in unnecessary chemotherapy for UK breast cancer patients

12 December 2016
New data demonstrate that Oncotype DX can help guide treatment decisions before breast cancer surgery enabling more personalised care, including avoidance of full mastectomy

10 October 2016
Large study shows older breast cancer patients have worse outcomes

20 June 2016
Updated NICE quality standard recommends Oncotype DX® in early-stage breast cancer 

6 June 2016
Oncotype DX presentations at 2016 ASCO® annual meeting reinforce Genomic Health’s leadership in optimising breast cancer treatment

31 May 2016
Innovative Oncotype DX test available in centres throughout West of Scotland Cancer Network to guide treatment decisions for early breast cancer patients

11 March 2016
Five-year outcomes results from European ‘PlanB’ study show that breast cancer patients with low Oncotype DX Recurrence Score® results can be spared chemotherapy despite having high-risk disease by traditional measures

14 December 2015
Major new study data demonstrates that the Oncotype DX test accurately predicts clinical breast cancer outcomes, bringing the total number of patients in prospective outcome studies to 50,000.

28 September 2015
Large TAILORx outcomes study demonstrates 99% of patients with low Oncotype DX Recurrence Score results were breast cancer relapse-free following five years of hormone therapy alone.

5 February 2015
As of April 1, 2015, the Oncotype DX test will be available, through an access scheme, as an option to help NHS clinicians in England decide whether to prescribe chemotherapy in people with early breast cancer.

UK Media Coverage

The Oncotype DX® assay has been featured in many UK national and local newspapers. Below are some stories which may be of interest to you:

Contact Us

Get in Touch
Making cancer care smarter.™

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.